THE PREDICTION OF RELAPSE AFTER DRUG TREATMENT OF GRAVES' DISEASE BY ASSAY OF LONG ACTING THYROID STIMULATOR-PROTECTOR (LATS-P)

Publisher Website
Google Scholar
Abstract
In a study of 52 patients with Graves'' disease followed for 1 yr after stopping antithyroid drugs [carbimazole, propylthiouracil], a strong relationship was found between serum LATS-P [long-acting thyroid stimulator-protector] and relapse. In those with serum LATS-P activity on stopping therapy, 21 (88%) of 24 relapsed. In those with no LATS-P activity on stopping antithyroid drugs only 8 (29%) of 28 relapsed and in 5 LATS-P was detectable at relapse. The overall prevalence of positive assays for LATS-P at relapse (90%) was similar to that seen in untreated Graves'' disease.